Advertisement
Canada markets close in 5 hours 59 minutes
  • S&P/TSX

    22,360.60
    +101.44 (+0.46%)
     
  • S&P 500

    5,191.21
    +3.54 (+0.07%)
     
  • DOW

    39,128.59
    +72.20 (+0.18%)
     
  • CAD/USD

    0.7302
    +0.0014 (+0.19%)
     
  • CRUDE OIL

    79.25
    +0.26 (+0.33%)
     
  • Bitcoin CAD

    83,748.20
    -1,661.77 (-1.95%)
     
  • CMC Crypto 200

    1,316.26
    +16.17 (+1.24%)
     
  • GOLD FUTURES

    2,327.50
    +5.20 (+0.22%)
     
  • RUSSELL 2000

    2,054.07
    -1.07 (-0.05%)
     
  • 10-Yr Bond

    4.4960
    +0.0040 (+0.09%)
     
  • NASDAQ

    16,286.85
    -15.91 (-0.10%)
     
  • VOLATILITY

    13.28
    +0.28 (+2.15%)
     
  • FTSE

    8,374.78
    +20.73 (+0.25%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • CAD/EUR

    0.6779
    +0.0003 (+0.04%)
     

Beyond Portola Pharmaceuticals' Disappointing Data

Trial results for its anticoagulant Betrixaban were a mixed bag, but it could still find its way to market and if not, another drug with a FDA approval date in August could still move the needle at Portola Pharmaceuticals.

This podcast was recorded on Mar. 30, 2016.